Vaxart to Host Investor Q&A Webcast
June 16, 2022 16:05 ET
|
Vaxart, Inc.
Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) --...
Vaxart Announces Adjournment of Annual Meeting of Stockholders
June 08, 2022 09:05 ET
|
Vaxart, Inc.
Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN...
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
June 03, 2022 08:00 ET
|
Vaxart, Inc.
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
June 02, 2022 08:30 ET
|
Vaxart, Inc.
Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to...
Vaxart to Participate at the Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
May 19, 2022 08:30 ET
|
Vaxart, Inc.
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif.,...
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
May 09, 2022 17:46 ET
|
Vaxart, Inc.
Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO,...
Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
April 14, 2022 08:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine...
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:05 ET
|
Vaxart, Inc.
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus...
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
February 24, 2022 08:30 ET
|
Vaxart, Inc.
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses...